据中国日报报道，12月27日，中核集团在苏州举办核技术医学转化与临床应用大会，并与苏州市联合宣 布：我国首个核医疗示范基地——苏州大学附属第二医院（核工业总医院）浒关院区二期项目正式启 用。核工业总医院浒关二期集核技术精准诊疗、临床试验、医学创新、培训交流功能于一体，聚焦核医 疗及肿瘤、慢病防治等重点方向。 公司方面，据中证报表示，景业智能、中广核技等。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 中证报指出，核医疗正迎来政策红利与技术突破的双重催化，随着中国在核素制备、核药研发及核医疗 设备领域的自主化突破，核医疗产业将迎来加速发展。中国核医疗市场预计2025-2030年将保持高速增 长，到"十五五"末，年产值有望达到6000亿元左右。 ...

明日主题前瞻 1、商业航天 | 12月26日，上交所发布《上海证券交易所发行上市审核规则适用指引第9号——商业火箭企业适用科创板第五套上市标准》，从业务范围 及"硬科技"属性要求、取得标准、阶段性成果等方面对商业火箭企业适用科创板第五套上市标准作出了细化规定，旨在加快推进商业航天创新发展、主动服 务航天强国战略。 点评：中泰证券认为，资本的精准配置将加速推动企业攻克火箭回收、大推力发动机等核心技术，推动中大型可重复使用火箭从研发走向规模化应用，逐步 缩小与国际领先水平的差距。同时，商业火箭产业将进一步牵引上下游先进材料、精密制造等领域协同升级，为卫星互联网组网、太空资源开发等国家战略 提供坚实支撑。 2、人工智能 | 据新华网，国家金融监督管理总局12月26日对外发布《银行业保险业数字金融高质量发展实施方案》，从数字金融治理、数字金融服务、数 字技术应用、数据要素开发、风险管理和监管数字化智能化转型等方面提出了33项工作任务。 点评：国泰海通认为，金融行业作为数据、信息与决策密集型产业，其数智化转型需求与大模型技术特性高度契合，已成为AI应用落地的绝佳"试验田"。金 融机构IT支出持续扩张，2023年科技投入 ...

从空间扩容到能力升级，核技术医学转化加速落地 言，二期投用并非简单的场地扩容，而是一次服务功能完善与服务能力升级的系统性提升。 据介绍，浒关院区二期将聚焦核医疗及肿瘤、慢病等重点方向，着力打造集核技术精准诊疗中心、核技术临床试验中心、核技术医学创新中心和核技术培 训交流中心于一体的一流核医疗示范基地，切实提升重大疾病防治与核应急医学救治能力。 12月27日，苏州大学附属第二医院(核工业总医院)浒关院区二期正式投用。当天，"中核集团核技术医学转化与临床应用大会"在浒关院区举行。对医院而 中核集团是我国核工业"国家队"和核技术应用产业链"链长"，2020年，集团与苏州市政府签署战略合作协议，开启核特色医疗等领域合作新篇章，本次投 用的总医院浒关二期是央地战略合作的重要成果之一。 活动中，中核集团"核技术医学应用场景创新促进中心"在核工业总医院揭牌，该中心将充分融合苏州区域生物医药产业优势和中核集团的研发能力、技术 优势，开放核医疗场景资源，建设放射性药物和高端核医疗装备应用的集成式场景。现场，中核粒子与核工业总医院首个战略合作实践成果"SPECT/CT临 床试验项目""IAEA肿瘤放射治疗质量保证团队区域培训项目 ...

昨天（12月27日），中核集团核技术医学转化与临床应用大会在核工业总医院/苏大附二院浒关院 区举行，总医院浒关二期正式投用。中国核工业集团有限公司总经理、党组副书记张涛，市委副书记、 市长吴庆文，苏州大学校长张桥出席活动。 中核集团总经济师、总审计师黄敏刚；苏州大学党委副书记、副校长沈明荣，市政府秘书长徐本， 苏州高新区和市有关部门主要负责同志等参加活动。 中核集团为我国核工业"国家队"和核技术应用产业链"链长"。2020年，集团与苏州市政府签署战略 合作协议，开启核特色医疗等领域合作新篇章。本次投用的总医院浒关二期是央地战略合作的重要成果 之一，聚焦核医疗及肿瘤、慢病等重点方向，着力打造集核技术精准诊疗中心、核技术临床试验中心、 核技术医学创新中心和核技术培训交流中心于一体的一流核医疗示范基地。 活动中，中核集团"核技术医学应用场景创新促进中心"在核工业总医院揭牌。该中心将充分融合苏 州区域生物医药产业优势和中核集团的研发能力、技术优势，开放核医疗场景资源，建设放射性药物和 高端核医疗装备应用的集成式场景。现场，中核粒子与核工业总医院首个战略合作实践成果"SPECT/CT 临床试验项目""IAEA肿瘤放射治 ...

Group 1 - The 2026 National People's Congress will convene on March 4 and 5, with the agenda including the review of the 15th Five-Year Plan draft [3][4] - From January to November, profits of large-scale industrial enterprises reached 66,268.6 billion yuan, a year-on-year increase of 0.1%, while November saw a 13.1% decline in profits compared to the previous year [3] Group 2 - The National People's Congress passed a revised Foreign Trade Law, effective from March 1, 2026, which includes provisions for aligning with international trade rules and promoting new trade models [4] - The total number of ETFs in the market reached 1,391, with a total scale of 6.03 trillion yuan, marking a growth of 354.52 billion yuan [6] Group 3 - At least 10 commercial space companies have initiated IPO processes, with five focusing on launch vehicles [6] - Since November, 95 companies related to the satellite industry have disclosed significant financing activities, with an overall financing balance of 690.55 billion yuan, reflecting a growth of over 45% compared to the previous year [7] Group 4 - The robot industry index has increased by 33.5% this year, with a high concentration of humanoid robots in the index components [8] - The market for elderly care products in China is projected to grow from 2.6 trillion yuan in 2014 to 5.4 trillion yuan by 2024 [10] Group 5 - The State Tobacco Monopoly Administration reported that since the regulation of e-cigarettes, nearly 20,000 administrative cases have been handled, with over 15 billion yuan involved [11] - The establishment of a standardization committee for humanoid robots and embodied intelligence was announced, focusing on key technologies and safety standards [12]

钛媒体App 12月27日消息，中核集团在苏州举办核技术医学转化与临床应用大会，并与苏州市联合宣 布：中国首个核医疗示范基地——苏州大学附属第二医院（核工业总医院）浒关院区二期项目正式启 用。核工业总医院浒关二期集核技术精准诊疗、临床试验、医学创新、培训交流功能于一体，聚焦核医 疗及肿瘤、慢病防治等重点方向。（广角观察） ...

此外，记者了解到，当日，中核集团还启动了核工业总医院-中核粒子SPET/CT临床试验项目、IAEA肿 瘤放射治疗质量保证团队区域培训项目，并揭牌成立核技术医学应用场景创新促进中心、依托核工业总 医院的江苏省工程研究中心等机构，标志着我国核技术医学应用在央地协同、产学研医深度融合方面取 得重要进展。 （文章来源：新华财经） 记者从中核集团获悉，中核集团首个核医疗示范基地——苏州大学附属第二医院（核工业总医院）浒关 院区二期项目27日正式启用。 据中核集团有关负责人介绍，作为中核集团重点工程项目及苏州市重大民生项目，核工业总医院浒关二 期项目集核技术精准诊疗、临床试验、医学创新、培训交流功能于一体，聚焦核医疗及肿瘤、慢病防治 等重点方向，着力构建"核技术精准诊疗、核技术临床试验、核技术医学创新、核技术培训交流"四大核 心功能中心，旨在成为推动核医疗技术研发、临床转化与人才培养的高地。示范基地的启用，将切实提 升我国重大疾病防治与核应急医学救治能力，成为推动核医疗技术自主创新与产业协同发展的重要引 擎。 ...

Core Viewpoint - Mianyang has made significant advancements in technological innovation during the "14th Five-Year Plan" period, establishing itself as a leading technology city in China, with a focus on integrating technological and industrial innovation [2] Group 1: Innovation Platforms - Mianyang has successfully established over 290 national and provincial innovation platforms, including the National Engineering Physics Cross-Science Research Center and key laboratories in aerodynamics and advanced radiation technology [3] - The city has achieved breakthroughs in core technologies, including the first e-FLASH radiotherapy device in China and the first X-FLASH device globally, with 10 achievements awarded national science and technology prizes [3] - The average annual R&D expenditure intensity in Mianyang reached 6.3%, maintaining a leading position nationally and first in the province [3] Group 2: Technology Transfer System - Mianyang has optimized the mechanism for matching supply and demand for technological achievements, conducting regular "school-enterprise dual-entry" activities and establishing various technology-industry integration platforms [4] - The city has initiated the construction of a national AI application pilot base and has developed 20 provincial and municipal pilot R&D platforms, enhancing the service capabilities of the public platform for pilot services [4] - The technology contract transaction volume surged from 1.4 billion yuan in 2020 to 22.5 billion yuan by 2025, marking an increase of over 16 times [4] Group 3: Industrial Innovation Capability - Mianyang has focused on cultivating high-energy industrial clusters, establishing the "587+" industrial system, and creating the first provincial intelligent robot training ground in the western region [5] - The city has signed 65 projects in various industrial parks, with total investments exceeding 35 billion yuan, and has initiated the construction of the "Photon Science and Technology City" [6] - The number of national-level specialized and innovative "little giant" enterprises reached 45, with over 3,500 technology-based SMEs expected to be registered in the year [6] Group 4: Institutional and Mechanism Reforms - Mianyang has pioneered comprehensive pilot reforms in talent evaluation in the province, benefiting over 2,000 technology talents [6] - The city has transformed over 500 national invention patents and generated nearly 70 million yuan in conversion revenue [6] - Mianyang has established a technology transaction and project incubation platform in Chengdu, facilitating low-cost R&D bases for local enterprises [6] Group 5: Science Popularization and Financial Support - Mianyang has hosted the China (Mianyang) Science and Technology City International Science and Technology Expo for 13 consecutive years, showcasing over 30,000 technological achievements [7] - The city has implemented various innovative policies to support technological innovation, securing over 1.5 billion yuan in funding for innovation entities [7] - The total loan balance for technology-based enterprises in Mianyang exceeded 80 billion yuan, promoting innovation and entrepreneurship across society [7]

Core Viewpoint - China Tongru (01763) has been recognized for its ESG practices at the ESG China Innovation Annual Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the "China ESG Excellence Practice (2025)" award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the "China ESG Listed Central Enterprises Pioneer 100 (2025)" by the China Central Radio and Television [1] Group 2: Technological Innovation - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It focuses on addressing critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It has innovated a circular economy development model for nuclear technology applications, achieving a balance between economic, environmental, and social benefits [1]

Core Viewpoint - China Tongru (01763) has been recognized for its ESG practices at the ESG China Innovation Annual Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the China ESG Excellence Practice (2025) award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the China ESG Listed Central Enterprises Pioneer 100 (2025) by the China Central Radio and Television [1] Group 2: Innovation and Development - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It focuses on addressing critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It has innovated a circular economy development model for nuclear technology applications, achieving synergy between economic, environmental, and social benefits [1]